Khiron Life Sciences Expands Skincare Leadership Team With The Appointment Of Dr. Edwin Bendek as Medical Director, Skincare

TORONTO,/CNW/ - Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today the appointment of Dr. Edwin Bendek MD, MA, MPH as Medical Director, Skincare. This appointment expands the Company’s scientific expertise and resources for future product and brand development, global strategic alliances and research and education initiatives across Latin America.

Andres Galofre, Khiron Co-founder and VP Business Development, stated, " The appointment of Dr. Bendek is an important addition to our skincare unit as we ramp up retail distribution, and further advance new product research and development. Dr. Bendek’s proven skincare and cosmetology experience, together with his exceptional industry network will be invaluable as we execute our research-based, product development strategy.”

Dr. Bendek, brings 20 years of global experience in general dermatology, cutaneous surgery, anti-aging dermatology and predictive genetics. A graduate of Medical Dermatology from Universidad Javeriana, Colombia, specialist in anti-aging from the WOSIAM in Paris, Master in Public Health from the Universidad de Granada, Master in Bioethics, Health and Law from the Université de Rennes and Specialist in clinical trials from Harvard University, Dr. Bendek is a regular speaker at national and international events, and is considered a pioneer in CBD cosmeceutical product development.

Khiron’s skincare unit, which operates within the Company’s previously announced Wellness unit, developed Kuida^®, It’s first consumer brand that brings the benefits of cannabidiol (CBD) to a comprehensive portfolio of skin and body care products for women. Kuida^® was launched in October, 2018 and is available to consumers in-store, online and through strategic ecommerce partnerships across Colombia.

Dr. Bendek, stated, “I am pleased to join the Khiron team at a very important time for our industry. CBD comseceutical products are rapidly gaining acceptance among retailers, health professionals and consumers who recognize the role these products can play in a beauty and health care regime. I look forward to working with my colleagues as we develop product innovations for an increasingly global market.”

About Khiron

Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming one of the first Colombian based medical cannabis companies to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Further information on Khiron Life Sciences can be found at https://investors.khiron.ca/

Cautionary Notes

Market and Industry Data
This press release contains market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of included information. Although management believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this press release, or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources.

Forward-Looking Statements
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements may be identified by statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Forward-looking statements herein include, but are not limited to, statements regarding the final acceptance of the TSXV and the commencement of sales in Mexico. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.